Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Major Shareholder Announcement5 Feb 2009
GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer5 Feb 2009
GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer30 Jan 2009
Genmab to Present at 27th Annual JPMorgan Healthcare Conference8 Jan 2009
Articles of Association of Genmab A/S dated December 17, 20085 Jan 2009
Genmab Announces Interim Results in Pivotal Study of Zalutumumab in Head and Neck Cancer5 Jan 2009
Genmab Sells Arzerra Co-Promotion Rights to GlaxoSmithKline18 Dec 2008
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
Grant of Warrants in Genmab A/S
17 Dec 2008
Genmab's Financial Calendar for 200910 Dec 2008
Arzerra(TM) (Ofatumumab) Demonstrates High Response Rates in Patients with Fludarabine Refractory Chronic Lymphocytic Leukaemia (CLL)8 Dec 2008
Genmab's Total Number of Voting Rights and Total Share Capital28 Nov 2008
Genmab to Present at 2008 Piper Jaffray Health Care Conference24 Nov 2008
  • Previous
  • 1
  • More pages
  • 108
  • 109
  • 110
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863